Serum level of human transforming growth factors β3 in Iraqi patient with chronic myeloid leukemia

The Philadelphia chromosome serves as the molecular marker for chronic myeloid leukemia (CML) result from fusion oncogene, leading to genetic instability including chromosomal aberrations and common altered genes that regulate cell proliferation and apoptosis. Transforming growth factor-β (TGF-β) signaling pathway is an important regulator of cellular functions, such as proliferation, differentiation, migration, and cell survival. The objective of this research was to investigate the role of TGFs-β3 as predictive biomarker on disease progression. This study includes three groups (50) individuals: newly diagnosed CML patients (male: 28 and female: 22), (50) CML chronic phase (male: 25 and female: 25), and (50) apparently healthy volunteers (male: 30 and female: 20). The National Center of Hematology at Mustansiriyah University admitted the patients. An analysis of each patient was diagnosed using a complete blood count, a bone marrow test, and a BCR-ABL gene test. ELISA technique was applied to assess the serum level of TGFs-β3. the results displayed high significant differences among patients (newly diagnosed) compared to the chronic phase, it was 59.7517 and 39.9167 pg/mL, respectively, and high significant differences among patients (newly diagnosed) compared to control, it was 59.7517 and 36.8861 pg/mL, respectively, as well as the serum level of TGF-β3, was elevated with some hematological marker. Elevated TGF-β levels can promote the development of myelofibrosis and some hematologic malignancies by influencing the immune system.